Renaissance Technologies’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Renaissance Technologies’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,299	Closed	-$107K	–	3993
2024 Q2	$107K	Buy	12,299 +2,000	+19%	+$17.7K	﹤0.01%	3172
2024 Q1	$90K	Buy	+10,299	New	+$84.9K	﹤0.01%	3393
2023 Q3	–	Sell	-3,660	Closed	-$26K	–	4219
2023 Q2	$26K	Buy	3,660 +827	+29%	+$6K	﹤0.01%	3731
2023 Q1	$21K	Buy	2,833 +506	+22%	+$4.3K	﹤0.01%	3817
2022 Q4	$16K	Buy	2,327 +180	+8%	+$1.58K	﹤0.01%	4000
2022 Q3	$22K	Sell	2,147 -5,037	-70%	-$63.7K	﹤0.01%	3887
2022 Q2	$88K	Buy	7,184 +6,077	+549%	+$96.1K	﹤0.01%	3880
2022 Q1	$23K	Buy	+1,107	New	+$38.3K	﹤0.01%	3996

Other funds holding TLIS

BCM

BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Renaissance Technologies's TLIS Position: Q3 2024 in Review

Renaissance Technologies sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 12,299 shares — an estimated $107K sold.

Renaissance Technologies first reported a position in TLIS in Q1 2022 and held it in 8 quarters. The position peaked at $107K in Q2 2024. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

Renaissance Technologies reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
Renaissance Technologies sold 12,299 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $107K.
Renaissance Technologies first reported a position in Talis Biomedical Corporation Common Stock in Q1 2022 and held it in 8 quarters.
Renaissance Technologies's Talis Biomedical Corporation Common Stock position peaked at $107K in Q2 2024.
2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on Renaissance Technologies's 13F filing for Q3 2024, filed 13 Nov 2024.